Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke
Wenbo Zhao,Sijie Li,Chuanhui Li,Chuanjie Wu,Junmei Wang,Lifei Xing,Yue Wan,Jinhui Qin,Yaoming Xu,Ruixian Wang,Changming Wen,Aihua Wang,Lan Liu,Jing Wang,Haiqing Song,Wuwei Feng,Qingfeng Ma,Xunming Ji,Jianping Ding,Pingping Wang,Yuan Wang,Xiaojun Hao,Bujv Bian,Guanqing Feng,Yujia Xie,Hui Wen,Xinlin Yang,Wenzhao Li,Yuejiang Gui,Jing Hao,Yaqiong Zhang,Qing Zhao,Yang Yang,Rutao Liu,Shanchao Zhang,Zhihui Si,Shan Qiao,Shan Xu,Jing Yuan,Yajuan Shao,Fang Dai,Guofeng Zhang,Yanchao Huo,Wenjing Zhou,Lu Yang,Xufei Cheng,Min Wang,Haidong Hou,Haiying Wang,Hongliang Yan,Yajuan Fu,Bowen Zang,Meiping Zhao,Pingping Wen,Jianying Lv,Xiaojing Lian,Meijuan Kang,Zaihang Zhang,Qing Zhang,Zaiyu Guo,Lianhua Zhao,Xiaoliang Liu,Jing Zheng,Shangsheng Ke,Lin Shao,Xiaoyan Liu,Xiaoming Tao,Yingbing Ke,Hao Liu,Dandan He,
DOI: https://doi.org/10.1001/jamaneurol.2024.0868
IF: 29.907
2024-04-22
JAMA Neurology
Abstract:Importance Evidence supports using antiplatelet therapy in patients with acute ischemic stroke. However, neurological deterioration remains common under the currently recommended antiplatelet regimen, leading to poor clinical outcomes. Objective To determine whether intravenous tirofiban administered within 24 hours of stroke onset prevents early neurological deterioration in patients with acute noncardioembolic stroke compared with oral aspirin. Design, Setting, and Participants This investigator-initiated, multicenter, open-label, randomized clinical trial with blinded end-point assessment was conducted at 10 comprehensive stroke centers in China between September 2020 and March 2023. Eligible patients were aged 18 to 80 years with acute noncardioembolic stroke within 24 hours of onset and had a National Institutes of Health Stroke Scale (NIHSS) score of 4 to 20. Intervention Patients were assigned randomly (1:1) to receive intravenous tirofiban or oral aspirin for 72 hours using a central, web-based, computer-generated randomization schedule; all patients then received oral aspirin. Main Outcome The primary efficacy outcome was early neurological deterioration (increase in NIHSS score ≥4 points) within 72 hours after randomization. The primary safety outcome was symptomatic intracerebral hemorrhage within 72 hours after randomization. Results A total of 425 patients were included in the intravenous tirofiban (n = 213) or oral aspirin (n = 212) groups. Median (IQR) age was 64.0 years (56.0-71.0); 124 patients (29.2%) were female, and 301 (70.8%) were male. Early neurological deterioration occurred in 9 patients (4.2%) in the tirofiban group and 28 patients (13.2%) in the aspirin group (adjusted relative risk, 0.32; 95% CI, 0.16-0.65; P = .002). No patients in the tirofiban group experienced intracerebral hemorrhage. At 90-day follow-up, 3 patients (1.3%) in the tirofiban group and 3 (1.5%) in the aspirin group died (adjusted RR, 1.15; 95% CI, 0.27-8.54; P = .63), and the median (IQR) modified Rankin scale scores were 1.0 (0-1.25) and 1.0 (0-2), respectively (adjusted odds ratio, 1.28; 95% CI, 0.90-1.83; P = .17). Conclusions and Relevance In patients with noncardioembolic stroke who were seen within 24 hours of symptom onset, tirofiban decreased the risk of early neurological deterioration but did not increase the risk of symptomatic intracerebral hemorrhage or systematic bleeding. Trial Registration ClinicalTrials.gov Identifier: NCT04491695
clinical neurology